Nautilus Biotechnology Inc (NAUT) - Total Assets
Based on the latest financial reports, Nautilus Biotechnology Inc (NAUT) holds total assets worth $200.91 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NAUT equity financing ratio to measure how much of total assets are equity-financed.
Nautilus Biotechnology Inc - Total Assets Trend (2018–2024)
This chart illustrates how Nautilus Biotechnology Inc's total assets have evolved over time, based on quarterly financial data. Explore NAUT strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Nautilus Biotechnology Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Nautilus Biotechnology Inc's total assets of $200.91 Million consist of 54.7% current assets and 45.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Nautilus Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NAUT stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nautilus Biotechnology Inc's current assets represent 54.7% of total assets in 2024, an increase from 0.9% in 2018.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2024, up from 0.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nautilus Biotechnology Inc Competitors by Total Assets
Key competitors of Nautilus Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Nautilus Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.95 | 16.65 | 25.73 |
| Quick Ratio | 14.95 | 16.65 | 25.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $125.34 Million | $135.54 Million | $74.64 Million |
Nautilus Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between Nautilus Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.37 |
| Latest Market Cap to Assets Ratio | 0.95 |
| Asset Growth Rate (YoY) | -20.6% |
| Total Assets | $242.74 Million |
| Market Capitalization | $231.14 Million USD |
Valuation Analysis
Near Book Valuation: The market values Nautilus Biotechnology Inc's assets close to their book value (0.95x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Nautilus Biotechnology Inc's assets decreased by 20.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nautilus Biotechnology Inc (2018–2024)
The table below shows the annual total assets of Nautilus Biotechnology Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $242.74 Million | -20.56% |
| 2023-12-31 | $305.56 Million | -12.71% |
| 2022-12-31 | $350.05 Million | -12.15% |
| 2021-12-31 | $398.45 Million | +368.70% |
| 2020-12-31 | $85.01 Million | +358.48% |
| 2019-12-31 | $18.54 Million | -87.28% |
| 2018-12-31 | $145.82 Million | -- |
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical… Read more